Get the Stockscreener App
0.8329
8.06%
0.0621
Pre-market:
.83
-0.0029
-0.35%
Atyr Pharma Inc stock is traded at $0.8329, with a volume of 3.11M.
It is up +8.06% in the last 24 hours and up +0.76% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$0.7708
Open:
$0.7699
24h Volume:
3.11M
Relative Volume:
0.30
Market Cap:
$81.61M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+8.85%
1M Performance:
+0.76%
6M Performance:
-83.80%
1Y Performance:
-74.99%
1-Day Range:
$0.7524
$0.8596
1-Week Range:
$0.7001
$0.8596
52-Week Range:
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.8329 | 75.53M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-15-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - PR Newswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
aTyr Pharma, Inc. $ATYR Shares Bought by Geode Capital Management LLC - Defense World
ATYR 5-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus
Shareholders SueWallSt in New Class Action Against aTyr Pharma, Inc.Act Now - Nasdaq
DEADLINE ALERT for ATYR, MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - PR Newswire
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of Upcoming December - GlobeNewswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) should c - GuruFocus
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors - GlobeNewswire
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATYR - Lelezard
Will aTyr Pharma Inc. (471A) stock profit from fiscal stimulusQuarterly Risk Review & Low Volatility Stock Recommendations - Newser
How aTyr Pharma Inc. (471A) stock valuation compares with sectorMarket Trend Review & Consistent Profit Trading Strategies - Newser
ATYR 1-WEEK DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - PR Newswire
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - MarketScreener
Bragar Eagel & Squire, P.C. Urgently Reminds Stockholders - GlobeNewswire
Lost Money on aTyr Pharma, Inc.(ATYR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securi - GuruFocus
Levi & Korsinsky Notifies aTyr Pharma, Inc. (ATYR) InvestorsLead Plaintiff Deadline on December 8, 2025 - Stockhouse
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATYR DEADLINE: Faruqi & Faruqi Reminds aTyr Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 8, 2025ATYR - PR Newswire
Shareholders of aTyr Pharma, Inc. (ATYR): Protect Your Rights Before December 8, 2025Contact Levi & Korsinsky - Stockhouse
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
ATYR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages - GlobeNewswire
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - Prime Publishers, Inc.
2025-11-28 | Securities Fraud Class Action Filed Against aTyr Pharma, Inc. (ATYR)Levi & Korsinsky Reminds Investors of December 8, 2025 | NDAQ:ATYR | Press Release - Stockhouse
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Announces that aTyr Pharma Investors Have Opportunity to Lead Class Action Lawsuit - MarketScreener
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
ATYR Deadline: ATYR Investors with Losses in Excess of $100K Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Your Wyoming Link
The Short List — Top 10 Most Shorted Stocks Right Now - Sahm
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman - GuruFocus
ATyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy -- Hagens Berman - MarketScreener
aTyr Pharma (ATYR) Securities Class Action Pending Over Key Drug's Efficacy — Hagens Berman - Morningstar
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves ForwardHagens Berman - The Malaysian Reserve
aTyr Pharma, Inc. Sued for Securities Law Violations - GlobeNewswire
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman - Barchart.com
Recover Investment Losses: Class Action Initiated Against aTyr Pharma, Inc. (ATYR) - Stockhouse
aTyr Pharma Faces Class Action after Clinical Trial Failure Raises Investor Concerns - TipRanks
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to - GuruFocus
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - WV News
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
You might want to take a look at Atyr Pharma Inc (ATYR) now - Setenews
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Atyr Pharma Inc Stock (ATYR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| Gross Jane A | Director |
Mar 17 '25 |
Buy |
4.00 |
3,750 |
15,000 |
9,750 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
| DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):